ClinicalTrials.gg
RecruitingNCT07380217UNLOAD-CHIPUpdated Feb 2, 2026

Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures

An interventional study of Mechanical circulatory support with the Pulsecath iVAC2L device in High-risk PCI and Coronary Artery Disease Risk High, sponsored by Amsterdam UMC, location VUmc. Recruiting at 8 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jan 2024, registered Jan 2026).
  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Coronary Artery Disease with a site in Netherlands — 44 open to participants now, 66 under way, 5 of them phase 3. Coronary Artery Disease · Netherlands.

Planned enrollment
156th of 198
98 · median 348
Started
2024
with 7 others
No phase
109 of 283
19 open now
Primary completion
2027-03
later than 38 of 65 live
Registered
278th of 283
by date
Lead sponsor
6 of 283
Amsterdam UMC, location VUmc

Among the 283 studies in Coronary Artery Disease with a site in Netherlands, this one is the 156th largest by planned enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2024, is one of 109 with no phase, reaches primary completion later than 38 of the 65 other live ones, and was the 278th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

44 of the 283 studies in Coronary Artery Disease with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Coronary Artery Disease with a site in Netherlands, or all of them as a file.
02

Study summary

If there is a narrowing or blockage in the coronary arteries of the heart, the cardiologist may choose to treat this blockage. This is called percutaneous coronary intervention (PCI), which involves both balloon angioplasty and the placement of a stent. PCI is a commonly performed and safe procedure. However, in your case, the procedure is more complicated than usual due to the location and nature of the narrowing, the required technique for the intervention, and the fact that your heart function is reduced. As a result, your PCI will carry a higher risk than usual.

During the procedure, balloons are inflated to clear the blockage, and a stent is placed to keep the artery open. This temporarily reduces or even stops the blood and oxygen supply to a large portion of the heart. This moment presents a higher risk for complications, such as low blood pressure or cardiac arrest. As a result, the heart may not pump blood effectively throughout the body, which can lead to oxygen deprivation in other organs.

To help the heart in this situation, it is possible to insert a mechanical heart pump during the procedure. This form of support is introduced via an artery in the groin into your left ventricle. The pump helps the heart function and may improve the circulation to the body's organs. On the other hand, the placement of the pump increases the chance of complications. Therefore, there are both potential benefits and risks. It is currently unclear whether PCI with the temporary pump can be performed more safely than without it.

This study aims to investigate whether mechanical circulatory support, specifically with the Pulsecath iVAC2L, leads to improved outcomes for patients undergoing high-risk PCI.

Read the detailed description

During the last three to four decades percutaneous coronary intervention (PCI) tools and techniques have improved immensely. Currently, PCI is the most widely used approach for myocardial revascularization. In general, elective PCI is considered a safe and relatively low-risk procedure.

However, patients with left main or complex coronary lesions or impaired left ventricular function remain at high risk for peri-procedural and post-procedural hemodynamic instability and death.

Mechanical circulatory support (MCS) devices, such as intra-aortic balloon pump (IABP) and Impella (Impella 2.5 and CP), have emerged as potential tools to avoid hemodynamic instability during these CHIP coronary interventions. These devices have shown to improve hemodynamics / cardiac output during complex PCI procedures, although the benefit of mechanical circulatory support in CHIP PCI remains debated and no clear benefit on patient outcomes has been shown. A recent large scale analysis favoured Impella as opposed to IABP. The use of these devices, especially Impella, is associated with increased risk for complications such as bleeding. The use of MCS for optimizing peri-procedural hemodynamic support needs to be balanced out against the potential risk for MCS related complications.

Recently the PulseCath iVAC 2L was introduced. This is a pulsatile pump, placed in the left ventricle, that ejects blood into the ascending aorta at a flow up to 2L/min. Theoretically, pulsatility maintains the physiological vascular responses and endothelial function at the level of the -systemic and -micro circulation and might offer benefit when compared to continues flow devices such as Impella. In contrast, IABP (which also offers pulsatile support), lacks the possibility of active unloading. Therefore, the combination of those features in the PulseCath iVAC2L is unique.

Recent studies performed with the PulseCath iVAC2L in the setting of CHIP PCI demonstrated hemodynamic advantages with afterload reduction, increased stroke volume and higher cardiac output. Also, the device was deemed safe in terms of complications. Samol et al. showed in a prospective cohort study that the use of IVAC2L was non-inferior to Impella in terms of feasibility and safety, even if complications occur. Other advantages of the IVAC2L are its relatively simple use and lower costs when compared to other mechanical circulatory support devices such as the Impella family. Considering that the IVAC2L is powered by an IABP console, the possibility of widespread use adds an even greater advantage.

So far, MCS facilitated CHIP has not been proven beneficial compared to a conservative (non-supported) high-risk procedure. Although high-risk criteria parameters such as coronary anatomy (location and complexity), co-morbid conditions, and concomitant cardiac disease (structural or valvular disease, left ventricular dysfunction) are well known, no intrinsic value of each of these components is determined. The recent PULSE trial shed some light on this gap of knowledge by showing possible additional hemodynamic benefit for patients with mitral regurgitation, who presented with an acute coronary syndrome (ACS) and who had higher cardiac filling pressures at baseline. Therefore, MCS-facilitated high-risk PCI might be beneficial if used in ACS patients or patients with (left-sided) congestion (stabilized acutely decompensated heart failure) with low hemodynamic tolerance. However, due to the low number of patients enrolled and non-randomized nature of this study, conclusions should be drawn with caution. To this day, no randomized controlled trials have been executed with the PulseCath iVAC2L in this subset of CHIP patients who are thought to benefit from an MCS-facilitated PCI. Its place in the setting of CHIP PCI remains to be elucidated.

Research hypothesis:

Prophylactic percutaneous mechanical left ventricular unloading by insertion of the PulseCath iVAC2L during complex coronary stenting (complex left main disease or equivalent or last remaining vessel) at risk for prolonged procedural ischemia in patients with severely reduced LV function is superior to a mechanical unassisted PCI procedure.

03

Conditions studied

  • High-risk PCI
  • Coronary Artery Disease Risk High

Keywords

  • High-risk PCI
  • CHIP
  • Mechanical Circulatory Support
  • Pulsecath iVAC2L
  • Pulsecath
  • iVAC2L
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years AND
  • Multidisciplinary heart team consensus for high risk PCI +/- MCS AND
  • Hemodynamically stable (SCAI A-B) AND
  • \<30% OR LVEF \<35% with moderate MR OR LVEF \<40% with severe MR AND
  • Complex left main disease (calcium modifying techniques deemed necessary OR 2-stent techniques, left dominant system) OR equivalent (ostial LAD and RCX) OR last remaining vessel (native).

Exclusion criteria

Exclusion Criteria:

  • for Pulsecath IVAC2L:

    1. severe aortic regurgitation
    2. known presence of an LV thrombus (contrast echo/MRI)
    3. Mechanical aorta valve prosthesis
    4. severe aortic valve stenosis
    5. peripheral arterial disease that would preclude placement of the PulseCath iVAC2L device
  • Cardiogenic shock defined as either SCAI CSWG stage C-E
  • Patient is intubated and mechanically ventilated
  • Stroke \<3 months
  • Major bleeding event \<3 months
  • History of bleeding diathesis or known coagulopathy (including heparin-induced thrombo-cytopenia), any recent GU or GI bleed, or will refuse blood transfusions.Renal replacement therapy
  • Pregnancy, or suspected thereof.
  • > 35
  • Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written and/or to comply with study procedures.
  • Subject belongs to a vulnerable population (defined as individuals with mental disability, persons in nursing homes, impoverished persons, homeless persons, nomads, refugees and those permanently incapable of giving informed consent; vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces and persons kept in detention).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • No intervention
    Standard-of-Care (without MCS)

    Patients will undergo high-risk PCI without upfront use of MCS

  • Experimental
    Pulsecath iVAC2L (with MCS)

    Patients will undergo high-risk PCI with upfront use of the Pulsecath iVAC2L (MCS)

    Device: Mechanical circulatory support with the Pulsecath iVAC2L device

Interventions

  • DeviceMechanical circulatory support with the Pulsecath iVAC2L device

    The Pulsecath iVAC2L is a pulsatile pump, placed in the left ventricle, that ejects blood into the ascending aorta at a flow up to 2L/min. Theoretically, pulsatility maintains the physiological vascular responses and endothelial function at the level of the -systemic and -micro circulation and might offer benefit when compared to continues flow devices such as Impella. In contrast, IABP (which also offers pulsatile support), lacks the possibility of active unloading. Therefore, the combination of those features in the PulseCath iVAC2L is unique.

06

What researchers measure

Primary outcomes

  1. Combined endpoint: - All-cause death - Cardiogenic shock (SCAI stage C-E) - (Need for) renal replacement therapy - (Need for) mechanical ventilation - Ventricular arrhythmias leading to loss of cardiac output requiring CPR

    Time frame: 30 days

Secondary outcomes

  1. PCWP (Δ max)

    Time frame: Periprocedural

  2. LVEDP (Δ max)

    Time frame: Periprocedural

  3. CO / CI / CPO (Δ max)

    Time frame: Periprocedural

  4. SvO2 (Δ max)

    Time frame: Periprocedural

  5. Drop in arterial pressure (MAP <60 OR SBP <90) for >10 minutes

    Time frame: Periprocedural

  6. Protected procedural success of Pulsecath iVAC2L

    Proper placement and circulatory support of the device. Moreover, the device should be successfully weaned on the cardiac catheterization laboratory and maximally within 1 hour post CHIP procedure.

    Time frame: Periprocedural

  7. Procedural success of Pulsecath iVAC2L

    Proper placement and circulatory support of the device. Moreover, the device should be successfully weaned \<6h post-procedural.

    Time frame: <6 hours post-PCI

  8. Rescue pVAD implantation

    Time frame: From index PCI through hospital discharge (up to 30 days)

  9. Highest Vasoactive Inotropic Score

    Time frame: From index PCI through hospital discharge (up to 30 days)

  10. Length of hospital stay

    Time frame: From index PCI through hospital discharge (up to 30 days)

  11. Cardiovascular death

    Time frame: 30 days

  12. Major adverse cardiovascular cerebral events (MACCE)

    Time frame: 30-days

  13. Stroke

    Time frame: 30-days

  14. PCI related myocardial infarction

    Time frame: 48 hours

  15. Myocardial infarction >48 hours post-PCI

    Time frame: 30-days

  16. Re-hospitalization or urgent hospital visit for heart failure

    Time frame: 30 days

Other outcomes

  1. Major vascular events

    Safety endpoint

    Time frame: 30 days

  2. Limb ischemia

    Safety endpoint

    Time frame: 30 days

  3. Bleeding events (BARC 3 and 5)

    Safety endpoint

    Time frame: 30 days

  4. Aortic valve injury

    Safety endpoint

    Time frame: 30 days

07

Study locations

8 of 8 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The publication rights in regard to the main results of the trial, i.e., regarding the primary and secondary objectives, belong to the sponsor. No individual investigator may publish on the results of this trial, or their own patients, without prior approval from the sponsor.

Supporting information: Study protocol

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 37 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Feb 2, 2026
StartActual
Jan 25, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07380217
Collaborators
Pulsecath BV.
Responsible party
Alexander Nap (Principal investigator, Amsterdam UMC, location VUmc) — Principal investigator
First posted
Feb 2, 2026
Start date
Jan 25, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Feb 2, 2026

Study contacts

Alexander Nap, MD, PhD
Contact
a.nap@amsterdamumc.nl
0031 020 444 4445
Tijmen H. Ris, MD
Contact
t.h.ris@amsterdamumc.nl
0031 020 444 4445

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion